Theriva Biologics announces investor presentations with updated corporate deck

Theriva Biologics, Inc.

Company to present to investors over next several weeks; updated deck filed as Exhibit 99.1.
Presentation titled 'Unique Oncolytic Virus Therapies for Multiple Solid Tumors' dated Jan 2026.
CEO Steven Shallcross signed the filing; stock trades on NYSE American under TOVX.
No specific financial or clinical data disclosed in the filing or exhibit text provided.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.